Drug kills prostate cancer
Doctors said that a new drug has succeeded greatly in the eradication of prostate cancer, and the results were amazing midwives in the two cases is to undergo surgery.
And stimulates new drug Ampelimamab (Ipilimumab) in the body's immune system to fight disease.
The doctors said that the success of the drug - developed by Bristol-Myers Squibb and Madarikis (Medarex), an American company of biotechnology - "exceeded all expectations."
He described Dr. Eugene Kohn, a specialist urology who was responsible for the treatment of patients experimental results as a "breakthrough", and as one of "the great secrets of prostate cancer research we were looking for for several years."
According to Professor Malcolm Mason from Cancer Research in Britain, "These reports are interesting and encouraging."
The men received treatment at Mayo Clinic in Minnesota, United States, one of the largest medical centers in the world.
Was diagnosed cases of Roger Nelson and Fraktoso Solano as an advanced stage of prostate cancer has spread the disease outside the prostate, which exceeded the cancer area of the abdomen in the case of Nelson, while the tumor SOULAN in the size of a golf ball, the two cases does not live behave with them more than a few months has, during which the patient "palliative care".
However, after the flow of the catalyst of the drug shrank tumors of the immune system enough to be removed surgically to both feet, where Wachovia completely and returned to their work. The two men were among a group of 108 patients who underwent the experiment.
The prostate cancer the most common cancer among men, and recorded it about 34 thousand cases a year and more than 10 thousand spend because of a year in Britain, which doubled the rates it occurs three times in the past 30 years, due mainly to improved detection. The United States is home to the highest rate of infection with this disease in the world.
And stimulates new drug Ampelimamab (Ipilimumab) in the body's immune system to fight disease.
The doctors said that the success of the drug - developed by Bristol-Myers Squibb and Madarikis (Medarex), an American company of biotechnology - "exceeded all expectations."
He described Dr. Eugene Kohn, a specialist urology who was responsible for the treatment of patients experimental results as a "breakthrough", and as one of "the great secrets of prostate cancer research we were looking for for several years."
According to Professor Malcolm Mason from Cancer Research in Britain, "These reports are interesting and encouraging."
The men received treatment at Mayo Clinic in Minnesota, United States, one of the largest medical centers in the world.
Was diagnosed cases of Roger Nelson and Fraktoso Solano as an advanced stage of prostate cancer has spread the disease outside the prostate, which exceeded the cancer area of the abdomen in the case of Nelson, while the tumor SOULAN in the size of a golf ball, the two cases does not live behave with them more than a few months has, during which the patient "palliative care".
However, after the flow of the catalyst of the drug shrank tumors of the immune system enough to be removed surgically to both feet, where Wachovia completely and returned to their work. The two men were among a group of 108 patients who underwent the experiment.
The prostate cancer the most common cancer among men, and recorded it about 34 thousand cases a year and more than 10 thousand spend because of a year in Britain, which doubled the rates it occurs three times in the past 30 years, due mainly to improved detection. The United States is home to the highest rate of infection with this disease in the world.
